Global Healthcare Analyst

Tina Banerjee

Equity research analyst having 15+ years of experience, with an interest on fundamentally strong global healthcare companies. I have been helping investors to find future winners in healthcare space to grow their wealth by focusing on the strength and potential of the business models of the companies. My initiating coverage reports and pitch help investors to know ‘what to buy’, ‘why to buy’, and ‘when to buy’. My clients always remain on top of the sector with the help of my timely and detailed notes on earnings or any news update. I also provide broader view on the entire healthcare sector through periodic thematic reports.

Equity Capital Markets

Star Sports Medicine / Equity Capital Markets

<ul>
<li>Star Sports Medicine, a medical device company specializing in clinical sports medicine solutions, has launched HK IPO consisting of 8.4M H shares at an offer price of HK$98.50 per share.</li>
<li>The company seeks to raise ~$105M to expand production capacity, fund R&amp;D efforts, and enhance commercialization capabilities. Subscriptions will close on April 29, with expected listing on May 5.</li>
<li>Despite negative impact from VBP and fierce competition from global players, the company is seeing marginal ASP improvement for its medical implants, which is leading margin recovery.</li>
</ul>


Star Sports Medicine, a medical device company specializing in clinical sports medicine solutions, has launched HK IPO consisting of 8.4M H shares at an offer price of HK$98.50 per share.
The company seeks to raise ~$105M to expand production capacity, fund R&amp;D efforts, and enhance commercialization capabilities. Subscriptions will close on April 29, with expected listing on May 5.
Despite negative impact from VBP and fierce competition from global players, the company is seeing marginal ASP improvement for its medical implants, which is leading margin recovery.


Shandong Weigao Group Medical Polymer (1066 HK)

스타 스포츠 메디신 IPO: 의료용 임플란트 사업 주도로 2025년 수익률 회복 전망에 희망 고조